Oscotec Inc. (KOSDAQ:039200)

Market Cap	1.40T -21.9%
Revenue (ttm)	144.18B +232.6%
Net Income	94.06B +2,111.2%
EPS	2,458.32 +2,110.3%
Shares Out	38.26M
PE Ratio	14.89
Forward PE	43.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	115,347
Open	38,350
Previous Close	38,000
Day's Range	36,150 - 38,550
52-Week Range	27,300 - 66,000
Beta	1.03
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Oscotec

Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 57
• Stock Exchange: KOSDAQ
• Ticker Symbol: 039200

Financial Performance

In 2025, Oscotec's revenue was 99.84 billion, an increase of 193.58% compared to the previous year's 34.01 billion. Earnings were 52.34 billion, an increase of 5871.65%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error